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Aims Retinal vessel analysis (RVA) represents a novel, non-invasive, and reliable method to study the microcirculation in
the eye. The goal of this study was to assess the extent of retinal microvascular dysfunction in patients with chronic
heart failure (CHF) compared to controls and established measures of vascular function.
...................................................................................................................................................................................................
Methods
and results
In this prospective, single-centre, observational study, 74 patients with compensated CHF (mean age
63.5 ± 11.2 years, 32% female, mean left-ventricular ejection fraction 37 ± 12.8%), 74 patients with cardiovascular
risk factors (CVRF; 64.1 ± 12.7 years, 34% female), and 74 healthy controls (HC; 57.8 ± 14.2 years, 35% female)
were included. The primary endpoint, flicker-induced dilatation of retinal arterioles (FIDart), was significantly
reduced in patients with CHF compared to CVRF and HC (mean FIDart 0.9 ± 0.2 vs. 2.3 ± 0.3 and vs. 3.6 ± 0.3%,
respectively, both P< 0.001 before and after propensity score-weighted analysis). Similar differences were seen for
venular FID. FIDart was less impaired in patients with dilated compared to ischaemic cardiomyopathy. No significant
differences were observed for arteriovenous ratio and flow-mediated dilatation. Impaired FIDven was associated
with echocardiographically estimated systolic pulmonary artery pressure and left atrial volume index.
...................................................................................................................................................................................................
Conclusion Retinal microvascular dilatation in response to flicker light is impaired in CHF. RVA may represent a new and useful
method to non-invasively monitor microvascular abnormalities in heart failure in an easy and standardized way
without the use of radiation.
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Introduction
Chronic heart failure (CHF) is a common cardiovascular disease
with a significant economic and societal burden. In the last
20 years, significant progress has been made in medical and de-
vice treatment of the disease. Yet, long-term prognosis of heart
failure patients remains poor and its pathophysiology is incom-
pletely understood.
Endothelial cells play a central role in blood vessel physiology by
regulating vessel wall integrity, vasodilatation and blood coagulation.
Impairment of their function (endothelial dysfunction) is a hallmark
feature of cardiovascular diseases,1 including heart failure2 and is
considered an early marker of elevated cardiovascular risk.3 Most
studies on endothelial dysfunction in heart failure focused on evalua-
tion of larger vessels such as brachial artery measurement of flow-
mediated vasodilatation (FMD).4–6 Recently, the role of the microvas-
culature in heart failure gained more attention.7,8 Yet, non-invasive
and radiation-free methods to evaluate microvascular dysfunction
are still scarce. Retinal vessel analysis (RVA) is a new and unique
method to evaluate the retinal microcirculation using flicker light-
stimulation and high-resolution measurement of retinal vessels.9
Flicker light-induced retinal dilatation has been found to involve nitric
oxide NO signalling and thereby represents a potential new
biomarker for microvascular endothelial dysfunction.10
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Our study was designed to test whether retinal microvascular
function as measured by flicker light-induced retinal arteriolar dilata-
tion (FIDart) is compromised in stable and compensated heart failure
patients compared to a cohort of healthy controls and patients with
cardiovascular risk factors without established cardiovascular disease.
Secondary objectives included the measurement of additional retinal
microvascular parameters and established tests of vascular function
(FMD and arterial stiffness) and correlation with heart failure-
relevant clinical parameters.
Methods
Study design and protocol
The study is a cross-sectional observational investigation of retinal micro-
vascular function in heart failure patients and controls in one university
centre. The study protocol was approved by the local ethics committee
(KEK-ZH-No. 2014-0329). All participants provided written informed
consent. Three groups of patients were prospectively recruited for the
study:
(i) Patients with a diagnosis of CHF according to the 2012 European
Society of Cardiology guidelines in currently compensated clinical status
and on stable pharmacologic therapy (CHF group). (ii) Patients currently
treated for a modifiable cardiovascular risk factor (hypertension, dyslipi-
daemia, smoking, and/or diabetes) without any known or symptomatic
cardiovascular disease (CVRF group). (iii) Healthy controls as defined by
non-smoking volunteers, aged 35 years and older, without any known
cardiovascular risk factor or any symptomatic or known cardiovascular
disease (HC group). Exclusion criteria were pregnancy or breastfeeding,
allergy against study drugs, photosensitive epilepsy, glaucoma, or other
significant eye pathologies such as blindness, inability to fixate, progressive
diabetic retinopathy, or prior retinal laser coagulation.
After signing informed consent, participants were invited to the main
study visit which was conducted in the morning and included a medical
history, measurement of clinical and laboratory parameters as well as vas-
cular function tests (vascular stiffness and RVA followed by flow-
mediated vasodilatation at the end of the examination). Patients were in-
structed to remain fasted for at least 8 h (except water), take their regular
medication as planned (except for antidiabetic medications), refrain from
coffee, alcohol and cigarette consumption for at least 12 h, avoid unusual
exercise the day before the examination and only present in stable medi-
cal state (i.e. free of infections or acute illnesses).
Retinal vessel analysis
RVA was conducted with an Imedos Dynamic Retinal Vessel Analyzer
(Imedos, Jena, Germany) using a Zeiss FF450 plus fundus camera (Carl
Zeiss Meditec AG, Jena, Germany) connected with two charge-coupled
device cameras that provide digital images for a computerized vessel anal-
ysis software (Imedos, Jena, Germany). Previously established measure-
ment protocols were used for the study.9,11 In brief, one eye was
randomly selected and mydriasis was induced using 0.5% tropicamide.
After 20 min, dynamic RVA was conducted with measurement of retinal
arteriolar and venular dilatation after provocation with 12.5 Hz optoelec-
tronic flicker light. This dilatation is majorly mediated by the release of ni-
tric oxide in response to increased oxygen consumption of retinal
photosensitive cells and involves neurovascular coupling.9,10 Nitric oxide
diffuses to vascular smooth muscle cells where it mediates vascular relax-
ation via activation of guanylate cyclase and increase in cyclic guanosine
monophosphate which activates protein kinase G. Analysis was per-
formed on temporal segments of one retinal arteriole and venule 0.5–2
optic disc diameters away from the optic disc. The selected vessel seg-
ments had to be sharp, free of branching sites and reflex stripes and sup-
plied at least one branch arteriole to the macula region. The protocol
consisted of a 50 s baseline and three 20 s flicker stimulations each fol-
lowed by a recovery period of 80 s. After acquisition, the results from the
three flicker periods were averaged and percent dilatation of arteriole or
venule from baseline (FIDart and FIDven, respectively) was calculated auto-
matically using the Imedos analysis software (Figure 1A). For static RVA,
monochromatic 50 fundus photographs were obtained using Visualis
and VesselMap 2 software (Imedos, Jena, Germany) and retinal arteries
and vein diameters in the area 0.5–1 optic disc diameters distant from the
optic disc were added with calculation of the central retinal artery and
vein equivalent (CRAE and CRVE; Figure 1B).11 CRAE and CRVE are plot-
ted in relative measuring units (mu). Both values were used to calculate
the arterio-venous ratio (AVR = CRAE/CRVE).
Flow-mediated vasodilatation
FMD was assessed using established protocols.3 In brief, arterial diameter
of one brachial artery was continuously measured using a 10 MHz linear
array transducer (Siemens Acuson X300, Siemens AG) with automatic
wall-tracking and analysis software (FMD-Studio, Pisa, Italy). One minute
after its application to the lower arm, the blood pressure cuff was inflated
50 mmHg above systolic pressure for 5 min. After release, hyperaemia
occurred and the change in arterial diameter was measured for further
10 min. The percent peak dilatation related to the baseline diameter
was calculated and depicted as FMD (%). To ascertain endothelial-
independent effects, pharmacological peak percent dilatation of the
brachial artery was measured 6 min after one dose of sublingual glycerol
trinitrate (GTN; Nitrolingual 0.4 mg, Pohl-Boskamp, Germany). The
reproducibility of our laboratory’s measurements was published.12
Arterial stiffness
Arterial stiffness was assessed by measuring pulse wave velocity (PWV)
and augmentation index (AIX) with a SphygmoCor applanation tonome-
ter system (AtCor Medical, Itasca, IL, USA) according to established pro-
tocols.13,14 Briefly, patients rest in the supine position for 15 min and
measurements are taken immediately after brachial blood pressure re-
cording. AIX was measured at the level of the radial artery by obtaining
ten high quality pulse wave measurements with automatic calculation of
AIX using the manufacturer’s proprietary software and after normalizing
to a heart rate of 75 beats per minute. PWV (meter/second) was calcu-
lated from the pressure wave transit time and distance between carotid
and femoral artery according to recent guidelines.13,15 Transit time be-
tween arterial sites was determined in relation to the R wave of the
electrocardiogram.
Echocardiography
Transthoracic echocardiographies were obtained during regular clinical
outpatients visits using M-mode, 2D and color Doppler echocardiogra-
phy by experienced cardiologists according to current guidelines.16 All
parameters were reanalysed by a single-blinded expert operator using
stored images. Left-ventricular ejection fraction (LVEF) was calculated
from biplane images using the Simpson’s method. Right ventricular frac-
tional area change (RVFAC) was defined as the ratio between the differ-
ence of the end-diastolic and end-systolic right ventricular areas and the
end-diastolic area. The measurements were corrected for body surface
area. Systolic pulmonary artery pressure (SPAP) was measured by addi-
tion of right atrial (RA) pressure, as determined by evaluation of inferior
vena cava diameter and variability, to the right ventricular (RV)–RA peak
systolic gradient as measured from the tricuspid regurgitant time-velocity
integral.
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Laboratory assessments
Blood samples were obtained in the fasted state using heparin plasma
vials at the beginning of the study visit and analyzed on the same day at
the Institute of Clinical Chemistry, University Hospital Zurich using
standard methods. High sensitivity troponin T and NT-proBNP
were quantified using electrochemiluminescence-immunoassays and
the COBAS8000 autoanalyzer of Roche Diagnostics (Mannheim,
Germany). Undetectable values were replaced by half the lower limit
of detection.17
Statistical analysis
Statistical analyses were computed with R (Rproject) and JMP 12.1
(SAS Institute, Cary, North Carolina, USA). The difference in FIDart
between heart failure patients, patients with cardiovascular risk fac-
tors and healthy controls represented the primary endpoint of the
study. The other vascular measures (FIDven, AVR, CRAE, CRVE, FMD,
PWV, and AIX) served as secondary exploratory outcomes. The re-
sults are reported as is and after inverse probability weighting to
achieve balance between groups. We aimed to carefully characterize
our prospectively recruited cohort and reported associations of
echocardiographic and laboratory findings with measures of vascular
dysfunction. Results are expressed as mean ± standard deviation (SD)
for baseline and predicted mean ± standard error (SE) for outcome
statistics unless otherwise noted. Sample size was estimated based on
data on FIDart of healthy controls by Mandecka et al.
18 Estimating a dif-
ference of FIDart of 1% (SD 2.1) with power of 80% and an alpha error
of 5%, a group size of 70 patients was calculated.
Differences in baseline characteristics (Supplementary material online,
Table S1) were tested. Categorical variables were analysed using v2 test
or Fisher’s exact test as appropriate. Continuous characteristics were
tested with one-way analysis of variance as omnibus and Student’s t-test
or Welch’s test for unequal variances post hoc. Non-normally distributed
data were compared using the Wilcoxon test. Normality was assessed vi-
sually by quantile–quantile plots.
To achieve between-group balance for possible confounders,19 gener-
alized covariate balancing propensity scores (CBPS, R package)20 and sub-
sequent inverse probability weights (IPW) were calculated. The
covariates patient age, sex, body mass index (BMI), systolic and diastolic
blood pressure, heart rate, total cholesterol, and fasting plasma glucose
were selected independently of our sample based on published
associations with the outcome and consideration of all possibly con-
founding group differences.21 As fasting plasma glucose concentration
was highly positively skewed (G1 = 3.32) and leptokurtic (excess kurto-
sis = 11.1), glucose is coarsened to a binary covariate with the World
Health Organization threshold of glucose > 5.6 mmol/L equalling im-
paired fasting glucose and glucose <_ 5.6 mmol/L corresponding to the cat-
egory normal fasting glucose.
Briefly, the CBPS method estimates propensity scores generalized for
multiple groups within the framework of generalized method of mo-
ments22 by modelling group assignment while simultaneously optimizing
covariate balancing. Stabilized and standardized IPW are consequently
calculated (R, package CBPS). Linear contrasts (R, package multcomp)
and robust ‘sandwich’ SEs were calculated for generalized linear models
(R, survey package) based on the weighted design. The P-values of LSD-
Fisher test results are reported. Predicted means are reported in the bar
graphs.
Linear regression was used to test the association of relevant echocar-
diographic and laboratory parameters with vascular function parameters.
NT-proBNP was linearized by taking the logarithm. To test the influence
of covariates on these associations, multiple linear regression analysis was
performed as a second step including the propensity score covariates
into the model.
Results
Baseline characteristics
Seventy four patients with CHF (mean age 63.5 ± 11.2 years; 32% fe-
male), 74 patients with cardiovascular risk factors without cardiovas-
cular disease (CVRF group; mean age 64.1 ± 12.7; 34% female), and
74 healthy controls (HC group; mean age 57.8 ± 14.2 years, 35% fe-
male) were eligible and included in the study between January 2015
and September 2016. Their clinical characteristics, laboratory param-
eters, and concomitant medication are presented in Table 1. Patients
with CHF were symptomatic (median New York Heart Association
class II), had a mean LVEF of 37 ± 12.8% and a median NT-proBNP of
706 ng/L (IQR 1161 ng/L) respectively. Patients with CHF were
somewhat older, had a higher BMI and a lower diastolic BP compared
to healthy controls. They had a higher rate of comorbidities, including
Figure 1 Retinal vessel analysis consists of a dynamic measurement of flicker-induced dilatation (FID) of retinal arterioles (red) and venules (blue)
using a standardized flicker protocol (A) and a static measurement arteriolar and venular diameters (B). The arteriovenous ratio (AVR) is calculated
from the central retinal vein and artery equivalent (CRAE and CRVE respectively).
Retinal vessel analysis in heart failure 49
Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/1/47/4554830
by University of Zurich user
on 09 March 2018
..
..
..
..
..
..
..
..
..
..
..
..smoking, hypertension, dyslipidaemia, and diabetes compared to
healthy controls. No significant differences were found for age, hy-
pertension, and dyslipidaemia compared to the patients with CVRF.
Clinical characteristics of the CHF group are shown in Table 2. The
aetiology of CHF was ischaemic cardiomyopathy (ICM; n= 34), di-
lated CM (DCM; n= 26), and other CM (n= 14).
Supplementary material online, Table S1 and Figures S1 (in
summary) and Figure S2 (for each covariate) show balance before
and after inverse probability weighting, whereas Supplementary
material online, Figure S3 shows weighted propensity score
overlap.
Retinal vascular function and structure
RVA was available for all participants except one healthy control due
to intolerance of the camera light. The primary endpoint (FIDart) was
....................................................................................................................................................................................................................
Table 1 Baseline characteristics
Parameter HC (n5 74) CVRF (n5 74) CHF (n5 74) PHC vs. CHF PCVRF vs. CHF
Clinical characteristics
Age (years) 57.8 ± 14.2 64.1 ± 12.7 63.5 ± 11.2 0.007 0.77
Female sex (n) 26 (35%) 25 (34%) 24 (32%) 0.73 0.86
BMI (kg/m2) 24.4 ± 3.5 25.9 ± 3.8 28.6 ± 5.3 <0.001 <0.001
Systolic BP (mmHg) 124.1 ± 11.3 138.6 ± 19.4 119.9 ± 20.6 0.15 <0.001
Diastolic BP (mmHg) 77.1 ± 8.1 83.6 ± 11.1 70.8 ± 12.5 <0.001 <0.001
Heart rate (beats/min) 63.7 ± 10.1 65.3 ± 10.2 65.4 ± 10.5 0.32 0.95
Comorbidities
Current smoking 0 (0%) 9 (12%) 17 (23%) <0.001 0.08
Hypertension 0 (0%) 52 (70%) 43 (58%) <0.001 0.12
Dyslipidaemia 0 (0%) 37 (50%) 42 (57%) <0.001 0.40
Diabetes mellitus 0 (0%) 7 (9%) 29 (39%) <0.001 <0.001
Laboratory parameters
Total cholesterol (mmol/L) 5.1 ± 0.6 5.1 ± 0.9 4.7 ± 1.5 0.02 0.03
HDL cholesterol (mmol/L) 1.7 ± 0.4 1.6 ± 0.5 1.2 ± 0.4 <0.001 <0.001
LDL cholesterol (mmol/L) 3.0 ± 0.6 2.9 ± 0.9 2.6 ± 1.2 0.009 0.07
Fasting plasma glucose (mmol/L) 5.2 ± 0.5 5.5 ± 0.9 6.8 ± 2.2 <0.001 <0.001
Impaired fasting plasma glucose (n) 17 (23%) 23 (31%) 25 (34%) <0.001 <0.001
CRP, high sensitivity (mg/L) [Median (IQR 25–75%)] 0.8 (0.4–1.55) 1.0 (0.5–1.55) 2.2 (1.2–4.7) <0.001 <0.001
Sodium (mmol/L) 140.9 ± 1.6 140.0 ± 2.6 139.2 ± 2.5 <0.001 0.03
Potassium (mmol/L) 3.9 ± 0.3 3.9 ± 0.3 4.1 ± 0.5 0.006 0.001
eGFR CKD-EPI (mL/min) 89.7 ± 17.1 83.7 ± 16.6 64.3 ± 21.4 <0.001 <0.001
NT-proBNP (ng/L) [Median (IQR 25–75%)] 58 (35–98) 61 (31–100) 706 (238–1399) <0.001a <0.001a
Troponin T, high sensitivity (ng/L) [Median (IQR 25–75%)] 2.5 (2.5–7) 5 (2.5–7.5) 13 (8–28) <0.001 <0.001
Concomitant medication
ACE inhibitor/ARB (%) 0 (0%) 40 (54%) 65 (88%) <0.001 <0.001
Beta blocker (%) 0 (0%) 18 (24%) 67 (91%) <0.001 <0.001
Mineralocorticoid antagonist (%) 0 (0%) 1 (1%) 44 (59%) <0.001 <0.001
Loop diuretic (%) 0 (0%) 2 (3%) 55 (74%) <0.001 <0.001
Calcium channel blocker (%) 0 (0%) 13 (18%) 9 (12%) 0.003 0.35
Thiazide diuretic (%) 0 (0%) 15 (20%) 12 (16%) <0.001 0.52
Aspirin (%) 3 (4%) 25 (34%) 42 (57%) <0.001 0.005
Anticoagulant (%) 0 (0%) 0 (0%) 27 (36%) <0.001 <0.001
Statin (%) 0 (0%) 34 (46%) 51 (69%) <0.001 0.005
Vitamin/mineral supplement (%) 23 (31%) 21 (28%) 27 (36%) 0.49 0.29
Non-insulin antidiabetic drugs (%) 0 (0%) 6 (8%) 18 (24%) <0.001 0.006
Insulin (%) 0 (0%) 1 (1%) 11 (15%) <0.001 0.001
Statistical analysis of continuous variables: One-way ANOVA with Student’s t post-test or Welch’s test as appropriate. Wilcoxon test was used for non-parametric data.
Statistical analysis of categorical variables: v2 test or Fisher’s exact test as appropriate. Significant post tests are only reported when overall ANOVA was significant.
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CHF, Patients with chronic heart failure; CRP, C-reactive
protein; eGFR CKD-EPI, estimated glomerular filtration rate as calculated by chronic kidney disease epidemiology collaboration formula; HC, healthy controls; HDL, high-den-
sity lipoprotein; IQR, inter-quartile range; LDL, low-density protein; NT-proBNP, N-terminal pro brain natriuretic peptide; CVRF, Patients with cardiovascular risk factors;
ANOVA, analysis of variance.
aAnalysis of NT-proBNP performed using logarithmic data.
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..significantly impaired in CHF patients compared with both
patients with CVRF and healthy controls (mean FIDart 0.9 ± 0.2 vs.
2.3 ± 0.3 and vs. 3.6 ± 0.2%, both P< 0.001 respectively, Table 3
and Figure 2). The primary endpoint was significant before and
after correction for baseline group imbalance by propensity score
analysis with inverse probability weighting (Supplementary mate
rial online, Table S2).
Results of secondary outcomes are shown in Table 3 and Figure 3.
Similar differences were found for the exploratory endpoint FIDven
with significantly lower venular dilatation in response to flicker light in
CHF patients compared to healthy controls (P= 0.027; Figure 3A).
CHF patients with DCM had a significantly higher FIDart compared
to CHF patients with ICM (mean FIDart 1.5 ± 0.3 vs. 0.4 ± 0.2,
P= 0.0045; Figure 3B and Table 4). There was no significant difference
in FIDart and FIDven between patients with HFpEF and HFrEF
(Supplementary material online, Figure S4).
In further exploration, although no significant differences in AVR,
CRAE, and CRVE were found between the groups (Table 3 and Figure
3C–E), CRVE tended to be higher in CHF patients compared to HC
(P= 0.071).
Other measures of vascular function
Both FMD and GTN-mediated vasodilatation of the brachial artery
were not significantly different between CHF and CVRF patients as
well as healthy controls (mean FMD 5.1 ± 0.3 vs. 5.6 ± 0.4 vs.
6.1 ± 0.7%, P= 0.32 and P= 0.17, respectively; Figure 4A and B). CHF
patients had increased arterial stiffness as evidenced by increased
PWV compared to healthy controls and patients with CVRF (mean
PWV 9.8 ± 0.4 vs. 7.3 ± 0.2 vs. 8.5 ± 0.3 m/s, P< 0.001 and P= 0.001,
respectively, Figure 4C). On the other hand, there were no significant
differences in AIXHR75 between CHF patients and CVRF patients and
healthy controls (Figure 4D).
Associations of vascular with clinical and
echocardiographic heart failure
parameters
Concerning the relationship between retinal function and structure,
there was no significant correlation between FIDart and AVR
(r= 0.02, P= 0.70). FMD correlated only weakly with FIDart (r= 0.15,
P= 0.03). Patients with CHF and diabetes had significantly lower
....................................................................................................................................................................................................................
Table 2 Baseline characteristics of heart failure subgroups
Parameter DCM (n526) ICM (n5 34) Other CMa (n5 14)
Clinical characteristics
Age (years) 62.2 ± 10.9 62.4 ± 11.7 68.4 ± 10.0
Female sex (n) 8 (31%) 8 (24%) 8 (57%)
BMI (kg/m2) 29.2 ± 5.7 27.5 ± 5.4 30.1 ± 4.3
Diastolic BP (mmHg) 75.8 ± 10.5 66.9 ± 12.3 71.1 ± 14.2
Current smoking (n) 9 (35%) 8 (24%) 0 (0%)
Diabetes mellitus (n) 5 (19%) 16 (47%) 8 (57%)
Coronary artery disease (n) 5 (19%) 34 (100%) 2 (14%)
Atrial fibrillation (n) 4 (15%) 3 (9%) 11 (79%)
ICD (n) 13 (50%) 17 (50%) 5 (36%)
CRT (n) 8 (31%) 7 (21%) 3 (21%)
NYHA-class (1–4) [Median (IQR 25–75%)] 2.0 (2–2) 2.0 (2–2.25) 2.0 (2–3)
Laboratory parameters
eGFR CKD-EPI (mL/min) 66.6 ± 20.5 67.6 ± 20.7 51.9 ± 22.4
NT-proBNP (ng/L) [Median (IQR 25–75%)] 444 (159–1157) 784 (364–1399) 910 (192–3300)
Troponin T, high sensitivity (ng/L) [Median (IQR 25–75%)] 10 (7–20) 14 (8–29) 21 (12–36)
Echocardiographyb
LVEF (%) (n¼ 74) 41 (31–48) 30 (26–40) 41 (23–54)
EDVI (mL/m2) (n¼ 72) 65 (53–108) 85 (66–95) 64 (51–127)
LAVI (mL/m2) (n¼ 72) 35 (28–38) 37 (32–42) 50 (38–71)
MR (Grade 0–3) (n¼ 72) 1 (0–1) 1 (0–1) 1 (0–1.25)
TAM (mm) (n¼ 70) 18 (17–19) 17 (13–20) 14 (13–18)
RVFAC (%) (n¼ 72) 40 (37–45) 39 (33–44) 35 (23–42)
SPAP (mmHg) (n¼ 71) 27.5 (23–44) 28 (25–44) 39.5 (27–49)
BMI, body mass index; CRT, cardiac resynchronization therapy; DCM, dilated cardiomyopathy; EDVI, end-diastolic volume index; ICD, implantable cardioverter defibrillator;
ICM, ischaemic cardiomyopathy; IQR, interquartile range; LAVI, left atrial volume index; LVEF, left ventricular ejection fraction; mPAPcalc, calculated mean pulmonary artery
pressure; MR, Grade of mitral regurgitation (Grade 0 none/minimal, Grade 1 mild, Grade 2 moderate, Grade 3 severe); NYHA, New York Heart Association; eGFR CKD-EPI,
estimated glomerular filtration rate as calculated by Chronic Kidney Disease Epidemiology Collaboration formula; TAM, tricuspid annulus motion; RVFAC, right ventricular frac-
tional area change.
aOther CM group includes valvular CM (n= 8), heart failure with preserved ejection fraction (n= 4), non-compaction CM (n= 1), chemotherapy-induced CM (n= 1).
bAll parameters are median (IQR 25–75% percentile in brackets).
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..FIDven compared to CHF patients without diabetes (FIDven 2.1 ± 0.29
vs. 3.2 ± 0.24, P= 0.004). No significant differences in FIDart, FMD,
CRAE, CRVE, and AVR were seen between CHF patients with and
without diabetes (data not shown).
With regard to laboratory markers related to heart failure and
prognosis, FIDven correlated negatively with log-scaled NT-proBNP
(r= -0.25, P= 0.04) and high sensitivity troponin T (r= -0.24, P= 0.04)
and positively with eGFR CKD-EPI (r= 0.27, P= 0.02; Supplementary
material online, Figure S5). There was no significant correlation with
FIDart and NT-proBNP, troponin T or eGFR CKD-EPI (r= -0.1,
P= 0.41, r= 0.15, P= 0.19, and r= 0.11, P= 0.33, respectively).
Figure 5 depicts the correlations of retinal venular function with
echocardiography measurements [on average 72 days (95% confi-
dence interval 41–112 days) apart from each other]. Interestingly,
FIDven correlated negatively with SPAP and left atrial volume index
(LAVI), a surrogate for chronically elevated left ventricular filling pres-
sure (r= -0.51, P< 0.001 and r= -0.33, P= 0.004, respectively). Both
correlations remained significant in the multiple linear regression
model including the covariates used in the propensity score, exclud-
ing systolic BP due to collinearity with diastolic BP (b= -4.84,
P< 0.001 and b= -2.81, P= 0.03, respectively). Weaker correlations
were found for FIDart with SPAP and LAVI (r= -0.29, P= 0.03 and
r= -0.20, P= 0.09 respectively; not significant after multivariate ad-
justment). There was no significant correlation of FIDart and FIDven
with LVEF. No significant correlation between FMD and SPAP, LAVI,
and LVEF was found (r= 0.06, P= 0.68; r= -0.07, P= 0.54 and
r= -0.04, P= 0.73 respectively).
Discussion
This systematic cross-sectional study on RVA in stable, compensated
heart failure patients for the first time showed that CHF is character-
ized by a profound alteration in retinal microvascular function as evi-
denced by significantly reduced flicker-light induced dilatation of the
arterial (primary endpoint) and venular vessels of the retina compared
to controls. In further exploration considering the positive endpoint,
retinal vascular responsiveness to flicker light was particularly impaired
in patients with ICM compared to those with DCM. In addition, the
extent of retinal venular dysfunction in CHF was correlated with
echocardiographic markers of left ventricular filling pressures.
Thus, RVA provides a unique window of opportunity to assess the
microcirculation in a standardized manner without the use of invasive
....................................................................................................................................................................................................................
Table 3 Vascular structure and function in heart failure patients and controls
Parameter HC (n5 74) CVRF (n574) CHF (n5 74) PHC vs. CHF PHC vs. CVRF PCVRF vs. CHF
Retinal vessel analysis
FIDart (%) 3.6 ± 0.3 2.3 ± 0.3 0.9 ± 0.2 <0.001 0.0019 <0.001
FIDven (%) 4.2 ± 0.4 3.7 ± 0.2 3.2 ± 0.3 0.027 0.19 0.22
AVR 0.84 ± 0.01 0.83 ± 0.01 0.82 ± 0.02 0.40 0.28 0.89
CRAE 181.3 ± 2.0 182.7 ± 2.5 183.7 ± 2.1 0.42 0.68 0.75
CRVE 216.3 ± 2.1 221.3 ± 2.4 224.6 ± 4.1 0.071 0.12 0.49
Flow-mediated dilatation
FMD (%) 6.1 ± 0.7 5.6 ± 0.4 5.1 ± 0.3 0.17 0.55 0.32
GTN (%) 17.0 ± 0.8 15.2 ± 0.8 14.3 ± 1.1 0.052 0.13 0.50
Arterial stiffness
PWV (m/s) 7.3 ± 0.2 8.5 ± 0.3 9.8 ± 0.4 <0.001 0.0011 0.0087
AIXHR75 (%) 23.5 ± 1.8 25.2 ± 1.2 25 ± 1.6 0.51 0.42 0.93
Results after IPW. IPW predicted means and ‘sandwich’ robust standard errors are shown. Significance reported from LSD-Fisher tests on contrasts from weighted generalized
linear models of parameter regressed against CHF subgroup.
AIX, augmentation index normalized to heart rate of 75/min, AVR, arteriovenous ratio, CRAE, central retinal artery equivalent; CRVE, central retinal vein equivalent; DCM,
dilated cardiomyopathy; FIDart, Flicker-induced dilatation of retinal arterioles; FIDven, Flicker-induced dilatation of retinal venules; FMD, flow-mediated vasodilatation; GTN,
glycerol trinitrate-mediated vasodilatation; HC, healthy controls; ICM, ischaemic cardiomyopathy; CVRF, patients with cardiovascular risk factors; PWV, pulse wave velocity;
IPW, inverse probability weighting.
P < 0.05 is significant (bold values).
Figure 2 Primary endpoint of the study with comparison of
flicker-induced dilatation of retinal arterioles (FIDart) between heart
failure patients (CHF), patients with cardiovascular risk factors
(CVRF) and healthy controls (HC). **P< 0.01, ***P< 0.001.
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or radiographic imaging modalities. Of note, the value of static
changes in the retinal vasculature in predicting cardiovascular events,
most prominently the relationship between retinal arteriole and ve-
nule diameters (AVR) has been well studied in larger prospective ob-
servational studies.23–25 However, less is known about dynamic
changes of retinal vessel reactivity in different forms of cardiovascular
disease or after therapeutic interventions. Smaller studies indicate re-
duced arteriolar and venular dilatation in patients with cardiovascular
risk factors, i.e. hypertension, hypercholesterolaemia, diabetes, and
obesity.9 We extend the findings to patients with heart failure, show-
ing profoundly impaired retinal dilatation compared to controls, that
remained robust after adjustment for cardiovascular risk factors and
possible haemodynamic confounders. The results are in line with a
smaller preliminary study showing significantly reduced FIDart in 16
patients with DCM compared to healthy controls.26 Interestingly,
retinal dilatation was even more profoundly impaired in ICM than in
DCM in our study cohort which may be related to the higher sys-
temic atherosclerotic burden in ICM patients compared to DCM.27
The pathophysiology of reduced flicker dilatation in patients with
CHF is presently a matter of investigation. Defects of endothelial NO
signalling in CHF are one possible mechanism. NO has been found to
be involved in retinal dilatation10 and, at the same time, endothelial
NO production is known to be reduced in heart failure, possible due
to inactivation by increased reactive oxygen species.2 Due to its easy
Figure 3 Secondary outcomes of retinal vessel analysis in heart failure patients and controls. Comparison of FIDven between heart failure patients
and controls (A) and FIDart between different heart failure subgroups (B). Static retinal vessel analysis with measurement of AVR (C) as calculated
from CRAE (D) and CRVE (E). *P< 0.05, **P< 0.01, ***P< 0.001. AVR, arteriovenous ratio; CRAE, central retinal artery equivalent; CRVE, central
retinal vein equivalent; DCM, dilated cardiomyopathy; FIDart, Flicker-induced dilatation of retinal arterioles; FIDven, Flicker-induced dilatation of retinal
venules; HC, healthy controls; ICM, ischaemic cardiomyopathy; CVRF, patients with cardiovascular risk factors.
....................................................................................................................................................................................................................
Table 4 Vascular structure and function in heart failure subgroups
Parameter DCM (n5 26) ICM (n5 34) Other CM (n514) PDCM vs. ICM PDCM vs. OCM
Retinal vessel analysis
FIDart (%) 1.5 ± 0.3 0.4 ± 0.2 0.8 ± 0.2 0.0045 0.0578
FIDven (%) 3.2 ± 0.3 3.4 ± 0.5 2.9 ± 0.4 0.70 0.69
AVR 0.85 ± 0.02 0.79 ± 0.03 0.83 ± 0.02 0.09 0.51
CRAE 186.2 ± 3.1 182.5 ± 3.5 179.0 ± 4.0 0.42 0.16
CRVE 220.2 ± 5.3 231.1 ± 5.6 220 ± 7.7 0.16 0.98
Flow-mediated dilatation
FMD (%) 5.1 ± 0.7 5.2 ± 0.4 4.8 ± 0.6 0.91 0.73
GTN (%) 13.1 ± 1.5 15.2 ± 2.2 15.7 ± 0.9 0.43 0.13
Arterial stiffness
PWV (m/s) 10.7 ± 0.7 9.3 ± 0.5 8.2 ± 1.0 0.088 0.041
AIXHR75 (%) 22.3 ± 3.1 26.7 ± 1.5 29.6 ± 1.5 0.20 0.031
Statistical analysis after IPW. IPW predicted means and robust ‘sandwich’ standard errors are reported. Significance reported from LSD-Fisher tests on contrasts from weighted
generalized linear models of parameter regressed against CHF subgroup.
AIX, augmentation index, as normalized to heart rate of 75/min; AVR, arteriovenous ratio; CRAE, central retinal artery equivalent; CRVE, central retinal vein equivalent; DCM,
dilated cardiomyopathy; FIDart, Flicker-induced dilatation of retinal arterioles; FIDven, Flicker-induced dilatation of retinal venules; FMD, flow-mediated vasodilatation; GTN,
glycerol trinitrate-mediated vasodilatation; HC, healthy controls; ICM, ischaemic cardiomyopathy; OCM, other cardiomyopathy group; RF, patients with cardiovascular risk
factors; PWV, pulse wave velocity; IPW, inverse probability weighting.
P < 0.05 is significant (bold values).
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applicability, RVA may in the future be useful in clinical practice to as-
sess risk in the context of cardiovascular prevention28 and to quantify
the effect of vascular targeted heart failure treatments as recom-
mended by the European guidelines.29 It is possible that such thera-
pies work better in patients with more pronounced endothelial
dysfunction and dynamic RVA may be helpful in selecting patients
that benefit most from such treatments.
In our study, we observed in contrast to previous studies4,30 no
significant difference in FMD, an established measurement of NO-
mediated vasodilatation of the brachial artery. One possible explana-
tion of this finding might be the compensated clinical status and the
baseline medical drug treatment of our patients with CHF. Indeed,
FMD is known to be improved by treatment with ACE inhibitors,
beta blockers, mineralocorticoid antagonists, or statins.2,30 As the
CHF patients in our study were well treated with respect to these
drugs, FMD in these patients may have already been partially re-
stored. Such restoration by disease-modifying drugs has not yet been
shown for retinal FID. Until longitudinal studies are available, this ex-
planation remains speculative and represents a limitation of the pre-
sent study. We observed only a weak positive correlation between
FMD and FID in our cohort, which was in line with a previous re-
port.31 There is a possibility that mechanisms beyond NO signalling
may be involved in retinal microvascular dysfunction in heart failure.
For example, there is evidence of close neurovascular coupling in the
retina allowing for a regulation of retinal vessels in response to neu-
ronal activation states and metabolic demands.19 Cognitive impair-
ment and both structural and functional neuronal alterations are
common in CHF.32 Hence, subclinical cellular dysfunction of retinal
nerve cells, even without overt retinopathy, may also underlie retinal
microvascular dysfunction in CHF.
Interestingly, impaired venular FID was associated with echocar-
diographically measured systolic pulmonary pressures and left atrial
volume. Both are indirect markers of elevated left ventricular filling
pressures in heart failure. Retinal microvascular dysfunction at the ve-
nous side may thus also be a consequence of myocardial and pulmo-
nary stiffening resulting in increased retinal congestion in CHF. This is
supported by the predominant correlation with venular dilatation
and the tendency of higher baseline venular diameters in CHF pa-
tients as measured by CRVE. While the venular microvasculature
might reflect high atrial pressure, the lack of association of arteriolar
FID with high pulmonary pressures suggests that systemic mecha-
nisms as discussed above are more dominant drivers of retinal dys-
function on the arterial side. An alternative explanation is that both
retinal vascular and myocardial dysfunction are mediated by the same
pathophysiologic changes, supported by the observation that pulmo-
nary hypertension and diastolic dysfunction are both associated with
alterations in NO signalling.33,34
Limitations
The study has some limitations. Due to the observational nature of
the study, unmeasured confounding between CHF patients and con-
trols is possible. The study was powered for FIDart and due to the
systematic approach of measuring several vascular parameters the
study may have been underpowered for detecting changes in second-
ary exploratory endpoints such as FMD. The CHF study cohort re-
flected the average distribution of patients in our heart failure
outpatient unit, resulting in enrichment of HFrEF patients. Although
we noted no significant differences, the study was not powered for
meaningful subgroup analyses (such as of HFpEF patients). Future
studies need to delineate whether retinal microvascular dysfunction
is prevalent in this heart failure subtype, which appears likely as mi-
crovascular dysfunction is thought to play an important pathogenic
role in HFpEF.8 Another limitation is the lower rate of diabetes in the
risk factor group compared to CHF patients. As we found no signifi-
cant difference in arteriolar FID between CHF patients with and with-
out diabetes, the observed differences in retinal microvascular
dysfunction are likely to be still largely mediated by the presence of
heart failure itself rather than the cumulative burden of individual risk
factors.
The correlation of echocardiographic parameters is hypothesis
generating. Echocardiograms were not performed on the same
day of the vascular function measurements but collected in clinical
routine. However, as LAVI is thought to reflect a slow anatomic
change of the left atrium, we are convinced of the consistency of
Figure 4 Secondary outcomes of established vascular measure-
ments in heart failure patients and controls. Flow-mediated (A) and
GTN-mediated (B) dilatation of the brachial artery in patients and
controls. Markers of arterial stiffness including PWV (C) and AIX
(D) among patients and controls. **P< 0.01, ***P< 0.001. AIX,
augmentation index, as normalized to heart rate of 75/min; FMD,
flow-mediated vasodilatation; GTN, glycerol trinitrate-mediated
vasodilatation; HC, healthy controls; CVRF, patients with cardiovas-
cular risk factors; PWV, pulse wave velocity.
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..our associations. Finally, our study was cross-sectional and fo-
cused on patients with symptomatic but compensated CHF on
stable evidence-based therapy. We cannot extend our findings to
patients with newly diagnosed, untreated or decompensated
heart failure and the temporal longitudinal evolution of microvas-
cular dysfunction in heart failure patients requires further study.
Until longitudinal data on the prediction of heart failure outcomes
by retinal microvascular dysfunction are available, the clinical ap-
plicability of this method is still limited.
Conclusion
In this first systematic study of both dynamic and static RVA in heart
failure, CHF patients were characterized by a reduction of retinal mi-
crovascular dilatation in response to flicker light. This association re-
mained significant after propensity score-weighted analysis. Impaired
retinal vascular function in CHF was correlated with echocardio-
graphic markers of diastolic dysfunction and pulmonary hypertension.
Dynamic RVA may be a new and useful parameter for assessing mi-
crovascular dysfunction in heart failure. Future studies will need to
delineate whether this method is useful for prognosis and prediction
of treatment response of disease-modifying therapies.
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Supplementary material is available at European Heart Journal online.
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